Please ensure Javascript is enabled for purposes of website accessibility

Why Amarin Corporation's Stock Is Falling Today

By George Budwell - Nov 12, 2018 at 10:33AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Amarin's lead drug lost some of its luster after a conference presentation over the weekend.

What happened

Shares of Amarin Corp. (AMRN -3.65%), a mid-cap Irish biopharma, fell by as much as 11.8% in pre-market trading Monday. The stock was down about 13% as of 10:30 a.m. EST. What's causing investors to hit the sell button?

Over the weekend, Amarin presented updated results from the large cardiovascular outcomes study, called Reduce-It, for its fish oil pill Vascepa in patients who have elevated triglyceride levels despite being on statin therapy, at the American Heart Association meeting in Chicago. While the results were overall positive, the presentation and an accompanying paper published in the New England Journal of Medicine seem to suggest that Vascepa's cardiovascular benefits might be overstated due to the use of mineral oil as the placebo. 

A doctor holding a red heart shape out in one hand.

Image source: Getty Images.

So what

In brief, patients receiving placebo exhibited an unexpected rise in so-called bad cholesterol levels, which may have exaggerated Vascepa's cardiovascular benefit in the study's patient population. This unintended result may give regulators pause when it comes to approving Vascepa's supplemental New Drug Application, slated to be submitted early next year. 

Now what

Should investors panic? Fortunately for shareholders, this placebo criticism doesn't appear to be enough to halt Vascepa's march toward another regulatory approval. Even the study's critics admitted that Vascepa does seem to provide some form of cardiovascular benefit; only the magnitude of this effect is in question. That fact alone should calm investors' collective nerves.  

And if that wasn't enough, H.C. Wainwright analyst Andrew Fein raised his 12-month price target on the stock to an eye-popping $51 a share (up from $31) after the conference presentation that's causing so much consternation this morning. In short, Amarin still has its fair share of bulls on Wall Street after this latest data release. Investors, therefore, may want to think twice before hitting the exits on this promising biopharma growth stock.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Corporation plc Stock Quote
Amarin Corporation plc
$1.85 (-3.65%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.